{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:09:37Z","timestamp":1761516577134,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.4158\/ep-2018-0296","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T11:22:29Z","timestamp":1533640949000},"page":"948-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biochemical Responses in Symptomatic and Asymptomatic Patients with Neuroendocrine Tumors: Pooled Analysis of Two Phase 3 Trials"],"prefix":"10.1016","volume":"24","author":[{"given":"Beloo","family":"Mirakhur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne E.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney F.","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandria T.","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Massien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilani","family":"Liyanage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Pitman","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2018-0296_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.4158\/EP-2018-0296_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jso.20179","article-title":"Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract","volume":"89","author":"Rorstad","year":"2005","journal-title":"J Surg Oncol"},{"journal-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) neuroendocrine tumors. Version 3.2017","year":"2017","author":"National Comprehensive Cancer Network","key":"10.4158\/EP-2018-0296_bb0020"},{"key":"10.4158\/EP-2018-0296_bb0025","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1245\/s10434-006-9148-z","article-title":"Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors","volume":"14","author":"Jensen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.4158\/EP-2018-0296_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","article-title":"Clinical presentation and diagnosis of neuroendocrine tumors","volume":"30","author":"Vinik","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.4158\/EP-2018-0296_bb0035","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/ajg.2010.154","article-title":"Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors","volume":"105","author":"Massironi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.4158\/EP-2018-0296_bb0040","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"key":"10.4158\/EP-2018-0296_bb0045","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4158\/EP14464.DSC","article-title":"AACE\/ACE disease state clinical review: diagnosis and management of midgut carcinoids","volume":"21","author":"Liu","year":"2015","journal-title":"Endocr Pract"},{"key":"10.4158\/EP-2018-0296_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.4158\/EP-2018-0296_bb0055","first-page":"25","article-title":"Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: symposium summary","volume":"44","author":"Pasieka","year":"2001","journal-title":"Can J Surg"},{"key":"10.4158\/EP-2018-0296_bb0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP-2018-0296_bb0065","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1245\/s10434-011-1997-4","article-title":"Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution","volume":"19","author":"Dahdaleh","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.4158\/EP-2018-0296_bb0070","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.ejca.2007.07.025","article-title":"Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours","volume":"43","author":"van der Horst-Schrivers","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.4158\/EP-2018-0296_bb0075","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.bjc.6603699","article-title":"The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract","volume":"96","author":"Formica","year":"2007","journal-title":"Br J Cancer"},{"key":"10.4158\/EP-2018-0296_bb0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","article-title":"Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center","volume":"8","author":"Janson","year":"1997","journal-title":"Ann Oncol"},{"key":"10.4158\/EP-2018-0296_bb0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-16-0392","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours","volume":"175","author":"Zandee","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0296_bb0090","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1136\/gut.2006.092320","article-title":"Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours","volume":"55","author":"Turner","year":"2006","journal-title":"Gut"},{"key":"10.4158\/EP-2018-0296_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.v17i3.484","article-title":"Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group","volume":"17","author":"Kocha","year":"2010","journal-title":"Curr Oncol"},{"key":"10.4158\/EP-2018-0296_bb0100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bpg.2005.05.007","article-title":"Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)","volume":"19","author":"de Herder","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.4158\/EP-2018-0296_bb0105","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.4158\/EP-2018-0296_bb0110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP-2018-0296_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.hoc.2015.09.008","article-title":"Role of somatostatin analogues in the treatment of neuroendocrine tumors","volume":"30","author":"Narayanan","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.4158\/EP-2018-0296_bb0120","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP-2018-0296_bb0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in meta-static enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0296_bb0130","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"ELECT Study Group","year":"2016","journal-title":"Endocr Pract"},{"key":"10.4158\/EP-2018-0296_bb0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.2017-0284","article-title":"Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot\/autogel: results from a randomized, placebo-controlled, double-blind and 32-week open-label study","volume":"23","author":"Fisher","year":"2018","journal-title":"Oncologist"},{"key":"10.4158\/EP-2018-0296_bb0140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cam4.435","article-title":"Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors","volume":"4","author":"Al-Efraij","year":"2015","journal-title":"Cancer Med"},{"key":"10.4158\/EP-2018-0296_bb0145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"Carcinoid syndrome: diagnosis and medical management","volume":"49","author":"van der Lely","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.4158\/EP-2018-0296_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000381715","article-title":"Impact of previous somatostatin analogue use on the activity of everolimus in patients with advanced neuroendocrine tumors: analysis from the phase III RADIANT-2 Trial","volume":"102","author":"Anthony","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP-2018-0296_bb0155","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.4158\/EP-2018-0296_bb0160","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1016\/S0959-8049(11)71875-5","article-title":"Correlation of PFS with early response of chromogranin A and 5-hydroxyindoleacetic acid levels in pts with advanced neuroendocrine tumours: phase III RADIANT-2 study results [6564 poster abstract]","volume":"47","author":"Baudin","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.4158\/EP-2018-0296_bb0165","unstructured":"PhanA, PavelM, CaplinM, et al. Long-term efficacy and safety with lanreotide autogel\/depot (LAN) from CLARINET and open-label extension (OLE) studies. 14th Annual ENETS Conference. March 8\u201310, 2017; Barcelona, Spain."},{"key":"10.4158\/EP-2018-0296_bb0170","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40262-015-0329-4","article-title":"Population pharmacokinetic analysis of lanreotide autogel\/depot in the treatment of neuroendocrine tumors: pooled analysis of four clinical trials","volume":"55","author":"Buil-Bruna","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.4158\/EP-2018-0296_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ecl.2010.12.008","article-title":"Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors","volume":"40","author":"Vinik","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP-2018-0296_bb0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MPA.0b013e318271c0d5","article-title":"A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs)","volume":"42","author":"Tellez","year":"2013","journal-title":"Pancreas"},{"key":"10.4158\/EP-2018-0296_bb0185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2013.10.025","article-title":"Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker","volume":"428","author":"Tohmola","year":"2014","journal-title":"Clin Chim Acta"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20354690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20354690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:05:06Z","timestamp":1761516306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20354690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1530891X20354690"],"URL":"https:\/\/doi.org\/10.4158\/ep-2018-0296","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical Responses in Symptomatic and Asymptomatic Patients with Neuroendocrine Tumors: Pooled Analysis of Two Phase 3 Trials","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2018-0296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}